氟西汀对孤独症谱系障碍儿童青少年强迫行为的影响:一项随机临床试验
该多中心随机安慰剂对照试验纳入146名7.5-18岁孤独症谱系障碍患者,评估氟西汀对强迫行为的疗效。16周时氟西汀组CYBOCS-PDD评分较基线下降3.72分,安慰剂组下降2.53分,组间差异-2.01分(95%CI -3.77至-0.25;P=0.03),但进一步校正后差异为-1.17分(95%CI -3.01至0.67;P=0.21)。结论受高脱落率和预设分析无显著结果限制。
要点
- 氟西汀组16周CYBOCS-PDD评分下降3.72分,安慰剂组下降2.53分。
- 校正分层因素后组间差异-2.01分(95%CI -3.77至-0.25;P=0.03)。
- 进一步校正后组间差异-1.17分(95%CI -3.01至0.67;P=0.21),未达统计学显著。
核心结论
- 在这项针对孤独症谱系障碍儿童青少年的初步研究中,与安慰剂相比,氟西汀治疗16周时强迫行为评分显著更低。
- 解释受高脱落率、校正潜在混杂因素和基线不平衡的预设分析无显著结果、以及治疗效应置信区间包含最小临床重要差异的限制。
研究设计与样本
- 多中心、随机、安慰剂对照临床试验,在澳大利亚3个三级健康中心开展。
- 共随机146名7.5-18岁孤独症谱系障碍患者,氟西汀组75例,安慰剂组71例。
- 入组标准为CYBOCS-PDD总分≥6分;入组时间2010年11月至2017年4月,随访至2017年8月。
主要发现
- 氟西汀组CYBOCS-PDD评分从基线12.80分降至16周9.02分(下降3.72分;95%CI -4.85至-2.60),安慰剂组从13.13分降至10.89分(下降2.53分;95%CI -3.86至-1.19)。
- 校正分层因素后,16周时组间平均差异为-2.01分(95%CI -3.77至-0.25;P=0.03)。
- 在进一步校正的预设模型中,组间差异为-1.17分(95%CI -3.01至0.67;P=0.21)。
- 146名随机参与者中109名完成试验,氟西汀组31例、安慰剂组21例脱落或未完成治疗。
关键数值与推荐
- 主要结局为随机化后16周时CYBOCS-PDD总分(范围0-20分,分数越高表示适应不良行为水平越高;最小临床重要差异为2分)。
- 研究药物第一周根据体重以4或8 mg/d开始,4周内滴定至最大剂量20或30 mg/d,治疗持续时间16周。
局限性
- 高脱落率。
- 校正潜在混杂因素和基线不平衡的预设分析无显著结果。
- 治疗效应的置信区间包含最小临床重要差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Selective serotonin receptor inhibitors are prescribed to reduce the severity of core behaviors of autism spectrum disorders, but their efficacy remains uncertain. OBJECTIVE: To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, placebo-controlled clinical trial. Participants aged 7.5-18 years with autism spectrum disorders and a total score of 6 or higher on the Children's Yale-Brown Obsessive Compulsive Scale, modified for pervasive developmental disorder (CYBOCS-PDD) were recruited from 3 tertiary health centers across Australia. Enrollment began November 2010 and ended April 2017. Follow-up ended August 2017. INTERVENTIONS: Participants were randomized to receive fluoxetine (n = 75) or placebo (n = 71). Study medication was commenced at 4 or 8 mg/d for the first week, depending on weight, and then titrated to a maximum dose of 20 or 30 mg/d over 4 weeks. Treatment duration was 16 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the total score on the CYBOCS-PDD (scores range from 0-20; higher scores indicate higher levels of maladaptive behaviors; minimal clinically important difference, 2 points) at 16 weeks postrandomization, analyzed with a linear regression model adjusted for stratification factors (site, age at baseline, and intellectual disability), with an additional prespecified model that included additional adjustment for baseline score, sex, communication level, and imbalanced baseline and demographic variables. RESULTS: Among the 146 participants who were randomized (85% males; mean age, 11.2 years), 109 completed the trial; 31 in the fluoxetine group and 21 in the placebo group dropped out or did not complete treatment. The mean CYBOCS-PDD score from baseline to 16 weeks decreased in the fluoxetine group from 12.80 to 9.02 points (3.72-point decrease; 95% CI, -4.85 to -2.60) and in the placebo group from 13.13 to 10.89 points (2.53-point decrease; 95% CI, -3.86 to -1.19). The between-group mean difference at 16 weeks was -2.01 (95% CI, -3.77 to -0.25; P = .03) (adjusted for stratification factors), and in the prespecified model with further adjustment, it was -1.17 (95% CI, -3.01 to 0.67; P = .21). CONCLUSIONS AND RELEVANCE: In this preliminary study of children and adolescents with autism spectrum disorders, treatment with fluoxetine compared with placebo resulted in significantly lower scores for obsessive-compulsive behaviors at 16 weeks. Interpretation is limited by the high dropout rate, null findings of prespecified analyses that accounted for potentially confounding factors and baseline imbalances, and CIs for the treatment effect that included the minimal clinically important difference. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12608000173392.
引用
- Reddihough DS, Marraffa C, Mouti A, et al. Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. JAMA. 2019. PMID: 31638682. doi:10.1001/jama.2019.14685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。